ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 315 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,286,613 | -11.5% | 47,884 | +17.4% | 0.00% | -33.3% |
Q2 2023 | $1,453,901 | +39.2% | 40,784 | -0.8% | 0.00% | +50.0% |
Q1 2023 | $1,044,385 | -39.7% | 41,117 | -3.8% | 0.00% | -50.0% |
Q4 2022 | $1,733,362 | +406.8% | 42,722 | +313.2% | 0.00% | +300.0% |
Q3 2022 | $342,000 | -7.1% | 10,340 | -0.9% | 0.00% | 0.0% |
Q2 2022 | $368,000 | -76.1% | 10,432 | -3.3% | 0.00% | -66.7% |
Q1 2022 | $1,538,000 | +10.0% | 10,791 | -48.8% | 0.00% | 0.0% |
Q4 2021 | $1,398,000 | -8.9% | 21,069 | -14.3% | 0.00% | 0.0% |
Q3 2021 | $1,534,000 | -44.0% | 24,574 | -25.7% | 0.00% | -50.0% |
Q2 2021 | $2,739,000 | +138.0% | 33,068 | +90.6% | 0.01% | +100.0% |
Q1 2021 | $1,151,000 | +20.1% | 17,351 | +39.1% | 0.00% | 0.0% |
Q4 2020 | $958,000 | +3.8% | 12,475 | -41.8% | 0.00% | 0.0% |
Q3 2020 | $923,000 | +7.3% | 21,443 | +7.7% | 0.00% | 0.0% |
Q2 2020 | $860,000 | +123.4% | 19,915 | +48.7% | 0.00% | +50.0% |
Q1 2020 | $385,000 | – | 13,393 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |